RemeGen Co., Ltd. (FRA:REG)

Market Cap	7.01B +4.8%
Revenue (ttm)	1.03B +286.2%
Net Income	750.14M
EPS	1.34
Shares Out	n/a
PE Ratio	9.35
Forward PE	21.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	8.19
Previous Close	8.13
Day's Range	8.19 - 8.19
52-Week Range	7.14 - 13.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 3,145
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: REG

Financial Performance

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error